BackLakeShore Biopharma Co Ltd. - Warrants (15/03/2028) Overview
LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)

LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) Return on Equity

Latest ROE for LakeShore Biopharma Co Ltd. - Warrants (15/03/2028): -86.78% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-86.78%

Return on Equity

-86.78%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) (YSBPW) FAQ

The latest ROE for YSBPW is -86.78%. That is below the sector sector average of -5.87%. Investors often review this figure alongside LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, YSBPW currently prints -86.78% for ROE, while the sector average sits near -5.87%. That is roughly 1378.8% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s growth, margins, and balance sheet.

Return on Equity shows how effectively LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) converts resources into returns. At -86.78%, YSBPW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting YSBPW's ROE (-86.78%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.